Free Trial
NASDAQ:RAPP

Rapport Therapeutics (RAPP) Stock Price, News & Analysis

Rapport Therapeutics logo
$10.51 +0.49 (+4.89%)
Closing price 03/14/2025 04:00 PM Eastern
Extended Trading
$11.03 +0.52 (+4.95%)
As of 03/14/2025 07:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Rapport Therapeutics Stock (NASDAQ:RAPP)

Key Stats

Today's Range
$10.29
$11.34
50-Day Range
$7.15
$17.99
52-Week Range
$6.43
$29.74
Volume
185,765 shs
Average Volume
166,523 shs
Market Capitalization
$384.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.00
Consensus Rating
Buy

Company Overview

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

Remove Ads

Rapport Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
36th Percentile Overall Score

RAPP MarketRank™: 

Rapport Therapeutics scored higher than 36% of companies evaluated by MarketBeat, and ranked 763rd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Rapport Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Rapport Therapeutics has received no research coverage in the past 90 days.

  • Read more about Rapport Therapeutics' stock forecast and price target.
  • Percentage of Shares Shorted

    10.37% of the float of Rapport Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Rapport Therapeutics has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Rapport Therapeutics has recently increased by 9.04%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Rapport Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Rapport Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.37% of the float of Rapport Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Rapport Therapeutics has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Rapport Therapeutics has recently increased by 9.04%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Rapport Therapeutics has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 16 news articles for Rapport Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    3 people have searched for RAPP on MarketBeat in the last 30 days.
Receive RAPP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rapport Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RAPP Stock News Headlines

Has Trump finally met his match?
Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance to walk away with gains as high as 235%, 459%, and 700% - all while the stock market got cut in half. Could he be right again?
Rapport Therapeutics sees cash runway through 2026
See More Headlines

RAPP Stock Analysis - Frequently Asked Questions

Rapport Therapeutics' stock was trading at $17.74 at the start of the year. Since then, RAPP shares have decreased by 40.8% and is now trading at $10.51.
View the best growth stocks for 2025 here
.

Rapport Therapeutics (NASDAQ:RAPP) released its quarterly earnings results on Thursday, November, 7th. The company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.57) by $0.07.

Rapport Therapeutics (RAPP) raised $136 million in an IPO on Friday, June 7th 2024. The company issued 8,000,000 shares at a price of $17.00 per share.

Rapport Therapeutics' top institutional shareholders include TRV GP V LLC (19.51%), T. Rowe Price Investment Management Inc. (4.47%), Price T Rowe Associates Inc. MD (3.13%) and Alliancebernstein L.P. (3.00%).
View institutional ownership trends
.

Shares of RAPP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Rapport Therapeutics investors own include Alpha Metallurgical Resources (AMR), Global X Copper Miners ETF (COPX), Hims & Hers Health (HIMS), Karuna Therapeutics (KRTX), Longboard Pharmaceuticals (LBPH) and Navios Maritime Partners (NMM).

Company Calendar

Last Earnings
11/07/2024
Today
3/15/2025
Next Earnings (Estimated)
6/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RAPP
Previous Symbol
NASDAQ:RAPP
Web
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$35.00
High Stock Price Target
$35.00
Low Stock Price Target
$35.00
Potential Upside/Downside
+233.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$384.41 million
Optionable
N/A
Beta
N/A
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:RAPP) was last updated on 3/15/2025 by MarketBeat.com Staff
From Our Partners